FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3186271152> ?p ?o ?g. }

• W3186271152 endingPage "1563" @default.
• W3186271152 startingPage "1555" @default.
• W3186271152 abstract "// Anjan Thakurta 1 , William E. Pierceall 1 , Michael D. Amatangelo 1 , Erin Flynt 1 and Amit Agarwal 2 1 Translational Medicine, Bristol Myers Squibb, Summit, NJ, USA 2 Global Medical Affairs, Bristol Myers Squibb, Summit, NJ, USA Correspondence to: Anjan Thakurta, email: anjan.thakurta@bms.com Keywords: multiple myeloma; combinations; immunomodulatory agents; apoptosis; protein degradation Received: March 19, 2021     Accepted: May 13, 2021     Published: July 20, 2021 Copyright: © 2021 Thakurta et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Multiple Myeloma (MM) is an incurable malignancy with current treatment choices primarily comprising combination regimens implemented with a risk-adapted approach. Cereblon (CRBN)-targeting immunomodulatory agents (IMiDs &#x00AE; ) lenalidomide (LEN) and pomalidomide (POM) play a central role in combination regimens due to their pleiotropic antitumor/immunomodulatory mechanisms that synergize with many anti-myeloma approved or developmental agents. Currently, more potent next generation cereblon E3 ligase modulators (CELMoDs &#x00AE; ) - iberdomide (IBER) and CC-92480 are in clinical development. With an expanding number of active agents/therapeutic modalities and a myriad of combinatorial possibilities, physicians and drug developers share an opportunity and challenge to combine and sequence therapies to maximize long-term patient benefit. Understanding drug mechanisms and their application in combination settings as well as the unique disease biology considerations from newly diagnosed (NDMM), relapsed/refractory (RRMM), and maintenance settings will be vital to guide the development of future MM therapies centered on a backbone of IMiD or CELMoD agents. Key aspects of drug activity are critical to consider while evaluating potential combinations: direct antitumor effects, indirect antitumor cytotoxicity, immune surveillance, and adverse side effects. In addition, the treatment journey from NDMM to early and late MM relapses are connected to genomic and immune changes associated with disease progression and acquisition of resistance mechanisms. Based on the types of combinations used and the goals of therapy, insights into mechanisms of drug activity and resistance may inform treatment decisions for patients with MM. Here we focus on the evolving understanding of the molecular mechanisms of CRBN-binding drugs and how they can be differentiated and suggest a strategic framework to optimize efficacy and safety of combinations using these agents." @default.
• W3186271152 created "2021-08-02" @default.
• W3186271152 creator A5000244748 @default.
• W3186271152 creator A5008229250 @default.
• W3186271152 creator A5028526208 @default.
• W3186271152 creator A5051117077 @default.
• W3186271152 creator A5076024121 @default.
• W3186271152 date "2021-07-20" @default.
• W3186271152 modified "2023-10-02" @default.
• W3186271152 title "Developing next generation immunomodulatory drugs and their combinations in multiple myeloma" @default.
• W3186271152 cites W1973999018 @default.
• W3186271152 cites W1985864219 @default.
• W3186271152 cites W1988998251 @default.
• W3186271152 cites W1992538067 @default.
• W3186271152 cites W2015345028 @default.
• W3186271152 cites W2021954218 @default.
• W3186271152 cites W2025656486 @default.
• W3186271152 cites W2048185240 @default.
• W3186271152 cites W2066713758 @default.
• W3186271152 cites W2071684411 @default.
• W3186271152 cites W2079076243 @default.
• W3186271152 cites W2081045803 @default.
• W3186271152 cites W2084778320 @default.
• W3186271152 cites W2091773528 @default.
• W3186271152 cites W2097860477 @default.
• W3186271152 cites W2125477622 @default.
• W3186271152 cites W2132258376 @default.
• W3186271152 cites W2135404380 @default.
• W3186271152 cites W2135915916 @default.
• W3186271152 cites W2136541422 @default.
• W3186271152 cites W2160295507 @default.
• W3186271152 cites W2161413435 @default.
• W3186271152 cites W2201190784 @default.
• W3186271152 cites W2394652810 @default.
• W3186271152 cites W2494443970 @default.
• W3186271152 cites W2528329272 @default.
• W3186271152 cites W2567188480 @default.
• W3186271152 cites W2606131188 @default.
• W3186271152 cites W2763809403 @default.
• W3186271152 cites W2766367793 @default.
• W3186271152 cites W2793911765 @default.
• W3186271152 cites W2793984127 @default.
• W3186271152 cites W2891710607 @default.
• W3186271152 cites W2900068404 @default.
• W3186271152 cites W2907794322 @default.
• W3186271152 cites W2912908455 @default.
• W3186271152 cites W2915026453 @default.
• W3186271152 cites W2945852816 @default.
• W3186271152 cites W2947874495 @default.
• W3186271152 cites W2955507058 @default.
• W3186271152 cites W2978510275 @default.
• W3186271152 cites W2979451218 @default.
• W3186271152 cites W2988470278 @default.
• W3186271152 cites W2988927877 @default.
• W3186271152 cites W2988984460 @default.
• W3186271152 cites W2989012859 @default.
• W3186271152 cites W3010457103 @default.
• W3186271152 cites W3044605664 @default.
• W3186271152 cites W3047048853 @default.
• W3186271152 cites W3085958492 @default.
• W3186271152 cites W3095138599 @default.
• W3186271152 cites W3095352143 @default.
• W3186271152 cites W87530790 @default.
• W3186271152 doi "https://doi.org/10.18632/oncotarget.27973" @default.
• W3186271152 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8310669" @default.
• W3186271152 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34316334" @default.
• W3186271152 hasPublicationYear "2021" @default.
• W3186271152 type Work @default.
• W3186271152 sameAs 3186271152 @default.
• W3186271152 citedByCount "21" @default.
• W3186271152 countsByYear W31862711522021 @default.
• W3186271152 countsByYear W31862711522022 @default.
• W3186271152 countsByYear W31862711522023 @default.
• W3186271152 crossrefType "journal-article" @default.
• W3186271152 hasAuthorship W3186271152A5000244748 @default.
• W3186271152 hasAuthorship W3186271152A5008229250 @default.
• W3186271152 hasAuthorship W3186271152A5028526208 @default.
• W3186271152 hasAuthorship W3186271152A5051117077 @default.
• W3186271152 hasAuthorship W3186271152A5076024121 @default.
• W3186271152 hasBestOaLocation W31862711521 @default.
• W3186271152 hasConcept C104317684 @default.
• W3186271152 hasConcept C134459356 @default.
• W3186271152 hasConcept C203014093 @default.
• W3186271152 hasConcept C25602115 @default.
• W3186271152 hasConcept C2776063141 @default.
• W3186271152 hasConcept C2776364478 @default.
• W3186271152 hasConcept C2777478702 @default.
• W3186271152 hasConcept C2778020697 @default.
• W3186271152 hasConcept C2778461978 @default.
• W3186271152 hasConcept C2778524551 @default.
• W3186271152 hasConcept C2778540781 @default.
• W3186271152 hasConcept C2779609412 @default.
• W3186271152 hasConcept C2909962599 @default.
• W3186271152 hasConcept C502942594 @default.
• W3186271152 hasConcept C55493867 @default.
• W3186271152 hasConcept C71924100 @default.
• W3186271152 hasConcept C86803240 @default.
• W3186271152 hasConceptScore W3186271152C104317684 @default.

• next